pfizer-biontech covid-19 vaccine- bnt162b2 injection, suspension
pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj) - pfizer-biontech covid-19 vaccine is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 6 months of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine supplied in a multiple dose vial with an orange cap and a label with an orange border, which is authorized for use in individuals 5 through 11 years of age. the vial labels state: age 5y to <12y. the carton labels state: for age 5 years to <12 years. do not administer pfizer-biontech covid-19 vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine [see description (13)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage i
pfizer-biontech covid-19 vaccine, bivalent- bnt162b2 original and omicron ba.4/ba.5 injection, suspension
pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), famtozinameran (unii: jsv288q5cv) (famtozinameran - unii:jsv288q5cv) - pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 12 years of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent. do not administer pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine or the pfizer-biontech covid-19 vaccine, bivalent [see description (13)] . risk summary no data are available regarding the use of pfizer-biontech covid-19 vaccine, bivalent during pregnancy. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, t
ibuprofen 200mg soft capsules
pfizer healthcare ireland - ibuprofen - capsule, soft - 200 milligram(s) - propionic acid derivatives; ibuprofen
celebrex 200 mg capsules, hard
pfizer healthcare ireland - celecoxib - capsule, hard - 200 milligram(s) - coxibs; celecoxib
celebrex 100 mg capsules, hard
pfizer healthcare ireland - celecoxib - capsule, hard - 100 milligram(s) - coxibs; celecoxib
dalacin c 150 mg hard capsules
pfizer healthcare ireland - clindamycin - capsule, hard - 150 milligram(s) - lincosamides; clindamycin
epanutin 50 mg hard capsules
pfizer healthcare ireland - phenytoin sodium - capsule, hard - 50 milligram(s) - hydantoin derivatives; phenytoin
epanutin 100 mg hard capsules
pfizer healthcare ireland - phenytoin sodium - capsule, hard - 100 milligram(s) - hydantoin derivatives; phenytoin
epanutin 25 mg hard capsules
pfizer healthcare ireland - phenytoin sodium - capsule, hard - 25 milligram(s) - hydantoin derivatives; phenytoin
feldene 10 mg capsules, hard
pfizer limited - piroxicam - capsule - 10 milligram(s) - oxicams; piroxicam